HEPARIN INJECTION 5,000 IU/ML
Source of information: Drugbank (External Link). Last updated on: 3rd July 18
*Trade Name used in the content below may not be the same as the HSA-registered product.
Active Ingredient / Synonyms
Calciparine | Eparina | Heparinate | Heparinic acid | Liquaemin | Panheprin | Unfractionated heparin | Heparin |
Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (factor IIa) and factor Xa. UH is different from low molecular weight heparin (LMWH) in the following ways: the average molecular weight of LMWH is about 4.5 kDa whereas it is 15 kDa for UH; UH requires continuous infusions; activated partial prothrombin time (aPTT) monitoring is required when using UH; and UH has a higher risk of bleeding and higher risk of osteoporosis in long term use. Unfractionated heparin is more specific than LMWH for thrombin. Furthermore, the effects of UH can typically be reversed by using protamine sulfate.
Unfractionated heparin is indicated for prophylaxis and treatment of venous thrombosis and its extension, prevention of post-operative deep venous thrombosis and pulmonary embolism and prevention of clotting in arterial and cardiac surgery. In cardiology, it is used to prevent embolisms in patients with atrial fibrillation and as an adjunct antithrombin therapy in patients with unstable angina and/or non-Q wave myocardial infarctions (i.e. non-ST elevated acute coronary artery syndrome) who are on platelet glycoprotein (IIb/IIIa) receptor inhibitors. Additionally, it is used to prevent clotting during dialysis and surgical procedures, maintain the patency of intravenous injection devices and prevent in vitro coagulation of blood transfusions and in blood samples drawn for laboratory values.
Mechanism of Action
Under normal circumstances, antithrombin III (ATIII) inactivates thrombin (factor IIa) and factor Xa. This process occurs at a slow rate. Administered heparin binds reversibly to ATIII and leads to almost instantaneous inactivation of factors IIa and Xa The heparin-ATIII complex can also inactivate factors IX, XI, XII and plasmin. The mechanism of action of heparin is ATIII-dependent. It acts mainly by accelerating the rate of the neutralization of certain activated coagulation factors by antithrombin, but other mechanisms may also be involved. The antithrombotic effect of heparin is well correlated to the inhibition of factor Xa. Heparin is not a thrombolytic or fibrinolytic. It prevents progression of existing clots by inhibiting further clotting. The lysis of existing clots relies on endogenous thrombolytics.
Unfractionated heparin is a highly acidic mucopolysaccharide formed of equal parts of sulfated D-glucosamine and D-glucuronic acid with sulfaminic bridges. The molecular weight ranges from 3000 to 30,000 daltons. Heparin is obtained from liver, lung, mast cells, and other cells of vertebrates. Heparin is a well-known and commonly used anticoagulant which has antithrombotic properties. Heparin inhibits reactions that lead to the clotting of blood and the formation of fibrin clots both in vitro and in vivo. Small amounts of heparin in combination with antithrombin III, a heparin cofactor,) can inhibit thrombosis by inactivating Factor Xa and thrombin. Once active thrombosis has developed, larger amounts of heparin can inhibit further coagulation by inactivating thrombin and preventing the conversion of fibrinogen to fibrin. Heparin also prevents the formation of a stable fibrin clot by inhibiting the activation of the fibrin stabilizing factor. Heparin prolongs several coagulation tests. Of all the coagulation tests, activated partial prothrombin time (aPTT) is the most clinically important value.
Heparin must be given parenterally as it is not absorbed through the gastrointestinal mucosa. It is usually given by iv infusion or deep sc injection. The onset of action is immediate after iv injection but can be delayed 20 to 60 minutes following sc injection. Plasma heparin concentrations may be increased and activated partial thromboplastin times (aPTTs) may be more prolonged in geriatric adults (older than 60 years of age) compared with younger adults.
40-70 mL/min (approximately the same as blood volume) Although heparin does not distribute into adipose tissues, clinicians should use actual body weight in obese patients to account for extra vasculature.
Liver and the reticulo-endothelial system are the sites of biotransformation. The metabolic fate of heparin is not well understood.
The drug appears to be removed mainly by the reticuloendothelial system. A small fraction of unchanged heparin also appears to be excreted in urine. Heparin cannot be eliminated by hemodialysis.
1.5 hours. The plasma half-life of heparin increases from about 60 minutes with a 100 unit/kg dose to about 150 minutes with a 400 unit/kg dose.
Adult Clearance = 0.43 ml/kg/min 25-28 weeks gestation = 1.49 ml/kg/min
In mouse, the median lethal dose is greater than 5000 mg/kg. Another side effect is heparin-induced thrombocytopenia (HIT syndrome). Platelet counts usually do not fall until between days 5 and 12 of heparin therapy. HIT is caused by an immunological reaction that makes platelets form clots within the blood vessels, thereby using up coagulation factors. It can progress to thrombotic complications such as arterial thrombosis, gangrene, stroke, myocardial infarction and disseminated intravascular coagulation. Symptoms of overdose may show excessive prolongation of aPTT or by bleeding, which may be internal or external, major or minor. Therapeutic doses of heparin give for at least 4 months have been associated with osteoporosis and spontaneous vertebral fractures. Osteoporosis may be reversible once heparin is discontinued. Although a causal relationship has not been established, administration of injections preserved with benzyl alcohol has been associated with toxicity in neonates. Toxicity appears to have resulted from administration of large amounts (i.e., about 100–400 mg/kg daily) of benzyl alcohol in these neonates. Its use is principally associated with the use of bacteriostatic 0.9% sodium chloride intravascular flush or endotracheal tube lavage solutions.
Although best effort has been made to ensure the information provided is correct and updated, users are advised to visit HSA Official website whenever in doubt. Please see Disclaimers.
We welcome all the content error reporting/feedback. Please contact us @ Text Us!
HEPARIN INJECTION 5,000 IU/ML was registered with Health Science Authority of Singapore by LEO PHARMA ASIA PTE LTD. It is marketed with the registration number of SIN00714P with effective from 1988-03-05.
This product contains 5000 iu/ml of Heparin in the form of INJECTION.
The medicine was manufactured by LEO Pharma A/S in DENMARK
It is a Presciption Only Medicine which can only be obtained from a doctor or a dentist, or from a pharmacist with a prescription from a Singapore-registered doctor or dentist.
Anatomical Therapeutic Chemical (ATC) Classification
Products Containing as Single Ingredient
|Drug ID||Trade Name||Active Ingredients||Forensic Class||Registrant||Status|
|1||DEXTROMETHORPHAN LINCTUS 15mg/5ml||Dextromethorphan||P Only||DRUG HOUSES OF AUSTRALIA PTE LTD||Active|
|22||ZENMOLIN SYRUP 2mg/5ml||Salbutamol||P Only||DRUG HOUSES OF AUSTRALIA PTE LTD||Active|
|41||APO-PROPRANOLOL TABLET 40mg||Propranolol||POM||PHARMAFORTE SINGAPORE PTE LTD||Active|
|42||APO-DIAZEPAM TABLET 2mg||Diazepam||POM||PHARMAFORTE SINGAPORE PTE LTD||Active|
|44||APO-DIAZEPAM TABLET 5mg||Diazepam||POM||PHARMAFORTE SINGAPORE PTE LTD||Active|
|45||APO-DIAZEPAM TABLET 10mg||Diazepam||POM||PHARMAFORTE SINGAPORE PTE LTD||Active|
|46||APO-PROPRANOLOL TABLET 10mg||Propranolol||POM||PHARMAFORTE SINGAPORE PTE LTD||Active|
|55||APO-ISDN TABLET 10mg||Isosorbide Dinitrate||POM||PHARMAFORTE SINGAPORE PTE LTD||Active|
|63||DIAPO TABLET 10mg||Diazepam||POM||BEACONS PHARMACEUTICALS PTE LTD||Active|
|64||FURMIDE TABLET 40mg||Furosemide||POM||BEACONS PHARMACEUTICALS PTE LTD||Active|
Products Containing as Mixture Ingredient
|Drug ID||Trade Name||Active Ingredients||Forensic Class||Registrant||Status|
|4||DIPHENHYDRAMINE EXPECTORANT||Ammonium Chloride|Diphenhydramine|Sodium Citrate||P Only||DRUG HOUSES OF AUSTRALIA PTE LTD||Active|
|5||DIPHENHYDRAMINE EXPECTORANT PAED.||Ammonium Chloride|Diphenhydramine|Sodium Citrate||P Only||DRUG HOUSES OF AUSTRALIA PTE LTD||Active|
|400||FAKTU SUPPOSITORY||Cinchocaine|Policresulen||P Only||TAKEDA PHARMACEUTICALS (ASIA PACIFIC) PTE LTD||Active|
|407||TRIMAXAZOLE TABLET||Sulfamethoxazole|Trimethoprim||POM||BEACONS PHARMACEUTICALS PTE LTD||Active|
|435||APO-SULFATRIM TABLET||Sulfamethoxazole|Trimethoprim||POM||PHARMAFORTE SINGAPORE PTE LTD||Active|
|508||APO-SULFATRIM PEDIATRIC TABLET||Sulfamethoxazole|Trimethoprim||POM||PHARMAFORTE SINGAPORE PTE LTD||Active|
|526||B.S. SUSPENSION||Sulfamethoxazole|Trimethoprim||POM||APEX PHARMA MARKETING PTE LTD||Active|
|583||CO-TRIMEXAZOLE SUSPENSION||Sulfamethoxazole|Trimethoprim||POM||BEACONS PHARMACEUTICALS PTE LTD||Active|
|676||BANEOCIN OINTMENT||Bacitracin|Neomycin||POM||NOVARTIS (SINGAPORE) PTE LTD||Active|
|678||BANEOCIN POWDER||Bacitracin|Neomycin||POM||NOVARTIS (SINGAPORE) PTE LTD||Active|